TSE:EXE Extendicare (EXE) Stock Price, News & Analysis C$14.66 -0.19 (-1.28%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About Extendicare Stock (TSE:EXE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Extendicare alerts:Sign Up Key Stats Today's RangeC$14.63▼C$14.9550-Day RangeC$12.27▼C$15.2252-Week RangeC$8.96▼C$15.32Volume73,559 shsAverage Volume182,837 shsMarket CapitalizationC$1.23 billionP/E Ratio15.19Dividend Yield3.33%Price TargetC$15.20Consensus RatingModerate Buy Company Overview Extendicare Inc., operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services. Read More Extendicare Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreEXE MarketRank™: Extendicare scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingModerate Buy Consensus RatingExtendicare has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Extendicare is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageExtendicare has only been the subject of 4 research reports in the past 90 days.Read more about Extendicare's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Extendicare is 15.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Extendicare is 15.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.84.Price to Book Value per Share RatioExtendicare has a P/B Ratio of 10.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXE. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldExtendicare pays a meaningful dividend of 3.40%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthExtendicare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Extendicare is 50.57%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Extendicare's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for EXE. News and Social Media2.6 / 5News Sentiment0.61 News SentimentExtendicare has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Extendicare this week, compared to 1 article on an average week.Search Interest30 people have searched for EXE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Extendicare insiders have not sold or bought any company stock.Percentage Held by Insiders13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.67% of the stock of Extendicare is held by institutions.Read more about Extendicare's insider trading history. Receive EXE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXE Stock News HeadlinesThe TSX Small Cap Index Is at Record Highs: 2 White-Hot Stocks to WatchOctober 2, 2025 | msn.comExtendicare Inc. (TSE:EXE) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 1, 2025 | americanbankingnews.comForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...October 9 at 2:00 AM | Brownstone Research (Ad)Public market insider selling at Extendicare (EXE)September 29, 2025 | theglobeandmail.comSeptember: The Worst Month for Stocks? Or the Best Buying Opportunity?September 20, 2025 | msn.com10% holder selling at Extendicare (EXE)September 17, 2025 | theglobeandmail.comHow I’d Structure My TFSA With $10,000 for Consistent Monthly IncomeAugust 13, 2025 | msn.comThis 4% Monthly Dividend Giant Never Stops PayingAugust 3, 2025 | msn.comSee More Headlines EXE Stock Analysis - Frequently Asked Questions How have EXE shares performed this year? Extendicare's stock was trading at C$10.63 at the beginning of the year. Since then, EXE stock has increased by 38.1% and is now trading at C$14.68. How were Extendicare's earnings last quarter? Extendicare Inc. (TSE:EXE) announced its quarterly earnings results on Tuesday, November, 12th. The company reported $0.19 earnings per share for the quarter. Extendicare had a trailing twelve-month return on equity of 64.13% and a net margin of 4.48%. Read the conference call transcript. How do I buy shares of Extendicare? Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Extendicare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE). Company Calendar Last Earnings11/12/2024Record date for 8/15 Dividend7/31/2025Ex-Dividend for 8/15 Dividend7/31/2025Dividend Payable8/15/2025Ex-Dividend for 9/15 Dividend8/29/2025Record date for 9/15 Dividend9/15/2025Dividend Payable9/15/2025Today10/09/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolTSE:EXE CIKN/A Webwww.extendicare.com Phone905-470-4000FaxN/AEmployees23,000Year FoundedN/APrice Target and Rating Average Price Target for ExtendicareC$15.20 High Price TargetC$18.00 Low Price TargetC$11.00 Potential Upside/Downside+3.8%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)C$0.97 Trailing P/E Ratio15.18 Forward P/E Ratio23.88 P/E GrowthN/ANet IncomeC$65.46 million Net Margins4.48% Pretax MarginN/A Return on Equity64.13% Return on Assets7.16% Debt Debt-to-Equity Ratio283.02 Current Ratio0.62 Quick Ratio0.98 Sales & Book Value Annual SalesC$1.51 billion Price / Sales0.81 Cash FlowC$4.58 per share Price / Cash Flow3.20 Book ValueC$1.40 per share Price / Book10.50Miscellaneous Outstanding Shares83,818,000Free FloatN/AMarket CapC$1.23 billion OptionableNot Optionable Beta0.88 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (TSE:EXE) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Extendicare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Extendicare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.